Pacira BioSciences, Inc. (PCRX)

Market Cap	1.25B
Revenue (ttm)	674.98M
Net Income (ttm)	41.96M
Shares Out	46.50M
EPS (ttm)	0.89
PE Ratio	30.12
Forward PE	9.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	491,074
Open	26.24
Previous Close	26.10
Day's Range	26.19 - 27.09
52-Week Range	25.74 - 48.60
Beta	0.75
Analysts	Strong Buy
Price Target	49.50 (+84.63%)
Earnings Date	May 1, 2024

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 712
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX

Financial Performance

In 2023, PCRX's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.

Analyst Forecast

According to 10 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $49.5, which is an increase of 84.63% from the latest price.

Price Target

$49.5

(84.63% upside)

Analyst Consensus: Strong Buy